MSLN and ovarian serous tumor: It is possible that—in addition to administering HIPEC with cisplatin—adding targeted therapy aimed at depleting PGRMC1, reducing mesothelin expression, and inhibiting Th2 infiltration could enhance the effectiveness of treatment and improve the longevity of patients with highly aggressive serous ovarian tumors of the PGR-negative type.